Furthermore, the temporally limited thrombosis enables selective tumor-treatment, and permits other anti-neoplastic therapies to be given in sequence before or after tTF-NGR reaching and accumulating in the tumor, yielding promising combination effects with other antitumor compounds [18]. Here, RHOH is linked to neoplasm.